Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G.

Blood. 2012 Sep 27;120(13):2650-7. Epub 2012 Aug 10.

2.

Effect of FCGR2A and FCGR3A variants on CLL outcome.

Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M.

Blood. 2010 Nov 18;116(20):4212-22. doi: 10.1182/blood-2010-03-272765. Epub 2010 Aug 12.

3.

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.

J Clin Oncol. 2007 Aug 20;25(24):3712-8.

PMID:
17704420
4.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H.

Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20. Erratum in: Lancet. 2011 Apr 2;377(9772):1154.

PMID:
21176949
5.

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G.

Br J Clin Pharmacol. 2012 Apr;73(4):597-605. doi: 10.1111/j.1365-2125.2011.04125.x.

6.

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.

Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.

7.

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B.

Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12.

PMID:
21564078
8.

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK.

Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11.

9.

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.

Kenkre VP, Hong F, Cerhan JR, Lewis M, Sullivan L, Williams ME, Gascoyne RD, Horning SJ, Kahl BS.

Clin Cancer Res. 2016 Feb 15;22(4):821-6. doi: 10.1158/1078-0432.CCR-15-1848. Epub 2015 Oct 28.

10.

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.

Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M, Indrak K.

Neoplasma. 2011;58(3):263-70.

PMID:
21395368
11.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.

PMID:
27282998
12.

Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.

Zhang W, Wang X, Li J, Duan MH, Zhou DB.

Chin Med J (Engl). 2010 Jan 20;123(2):198-202.

PMID:
20137370
13.

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ.

Oncology. 2012;83(4):218-27. doi: 10.1159/000341359. Epub 2012 Aug 16.

PMID:
22906996
14.

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.

Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A.

Haematologica. 2007 Aug;92(8):1127-30.

15.

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H.

Blood. 2002 Feb 1;99(3):754-8.

16.

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A.

Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.

17.

Treatment of older patients with mantle-cell lymphoma.

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.

N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.

18.

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.

Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.

PMID:
18930989
19.

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O.

J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806. doi: 10.1093/jnci/djr418. Epub 2011 Oct 21. Review.

PMID:
22021664
20.

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.

Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M.

J Clin Oncol. 2010 Oct 10;28(29):4480-4. doi: 10.1200/JCO.2010.28.4786. Epub 2010 Aug 9.

PMID:
20697092

Supplemental Content

Support Center